Total Payments
$7,301
2024 Payments
$559.71
Companies
19
Transactions
140
Medicare Patients
2,924
Medicare Billing
$806,100
Payment Breakdown by Category
Food & Beverage$7,263 (99.5%)
Education$38.10 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $7,263 | 137 | 99.5% |
| Education | $38.10 | 3 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| CIPLA USA INC. | $1,503 | 1 | $0 (2020) |
| Gilead Sciences, Inc. | $1,108 | 20 | $0 (2024) |
| ViiV Healthcare Company | $852.66 | 18 | $0 (2024) |
| Melinta Therapeutics, LLC | $811.51 | 37 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $541.19 | 7 | $0 (2023) |
| Insmed, Inc. | $529.58 | 19 | $0 (2024) |
| Merck Sharp & Dohme LLC | $392.37 | 15 | $0 (2023) |
| Allergan, Inc. | $384.96 | 3 | $0 (2020) |
| Ferring Pharmaceuticals Inc. | $289.06 | 2 | $0 (2023) |
| AbbVie Inc. | $246.83 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $559.71 | 7 | Gilead Sciences, Inc. ($383.22) |
| 2023 | $935.70 | 20 | Insmed, Inc. ($296.75) |
| 2022 | $887.56 | 9 | Melinta Therapeutics, LLC ($249.72) |
| 2021 | $509.42 | 12 | Paratek Pharmaceuticals, Inc. ($184.93) |
| 2020 | $2,106 | 11 | CIPLA USA INC. ($1,503) |
| 2019 | $671.70 | 32 | Melinta Therapeutics, Inc. ($271.71) |
| 2018 | $1,049 | 30 | Melinta Therapeutics, Inc. ($273.88) |
| 2017 | $581.28 | 19 | Gilead Sciences Inc ($162.80) |
All Payment Transactions
140 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/12/2024 | Melinta Therapeutics, LLC | Kimyrsa (Drug), Orbactiv, Rezzayo | Food and Beverage | In-kind items and services | $16.20 | General |
| Category: ANTIBIOTICS | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $121.90 | General |
| 05/20/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $14.03 | General |
| Category: Respiratory | ||||||
| 05/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $148.62 | General |
| 04/25/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $112.70 | General |
| Category: HIV | ||||||
| 02/15/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $119.74 | General |
| Category: HIV | ||||||
| 01/24/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: Respiratory | ||||||
| 12/01/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $25.56 | General |
| Category: Respiratory | ||||||
| 11/15/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $27.43 | General |
| Category: Respiratory | ||||||
| 10/27/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: Respiratory | ||||||
| 09/27/2023 | Ferring Pharmaceuticals Inc. | REBYOTA (Biological) | Food and Beverage | In-kind items and services | $157.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/22/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.50 | General |
| Category: Respiratory | ||||||
| 08/22/2023 | AbbVie Inc. | TEFLARO (Drug), AVYCAZ | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/18/2023 | Merck Sharp & Dohme LLC | DIFICID (Drug), RECARBRIO, ZERBAXA | Food and Beverage | In-kind items and services | $24.06 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 07/13/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $27.69 | General |
| Category: Respiratory | ||||||
| 06/22/2023 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $210.23 | General |
| Category: ANTIBIOTIC | ||||||
| 06/21/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $26.76 | General |
| Category: Respiratory | ||||||
| 05/31/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $8.45 | General |
| Category: Respiratory | ||||||
| 05/15/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $15.88 | General |
| Category: Respiratory | ||||||
| 05/06/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $3.97 | General |
| Category: Respiratory | ||||||
| 04/28/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $11.01 | General |
| Category: Respiratory | ||||||
| 04/12/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $24.32 | General |
| Category: Respiratory | ||||||
| 03/21/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $18.11 | General |
| Category: Respiratory | ||||||
| 03/02/2023 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $121.86 | General |
| Category: HCV | ||||||
| 02/28/2023 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $19.94 | General |
| Category: Respiratory | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 800 | 2,258 | $550,820 | $187,507 |
| 2022 | 4 | 697 | 2,412 | $585,019 | $203,953 |
| 2021 | 4 | 772 | 2,406 | $610,579 | $227,960 |
| 2020 | 4 | 655 | 1,887 | $525,265 | $186,680 |
Total Patients
2,924
Total Services
8,963
Medicare Billing
$806,100
Procedure Codes
17
All Medicare Procedures & Services
17 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 414 | 1,565 | $294,220 | $93,388 | 31.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 88 | 319 | $100,485 | $52,015 | 51.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 236 | 260 | $136,500 | $34,414 | 25.2% |
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Office | 2023 | 30 | 77 | $9,625 | $4,369 | 45.4% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 32 | 37 | $9,990 | $3,320 | 33.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 381 | 1,703 | $320,164 | $91,058 | 28.4% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 113 | 487 | $153,405 | $80,940 | 52.8% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 184 | 202 | $106,050 | $30,401 | 28.7% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 19 | 20 | $5,400 | $1,553 | 28.8% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 131 | 629 | $198,135 | $106,747 | 53.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 390 | 1,493 | $280,684 | $82,595 | 29.4% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 195 | 216 | $113,400 | $33,268 | 29.3% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 56 | 68 | $18,360 | $5,351 | 29.1% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 124 | 474 | $164,430 | $83,030 | 50.5% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 300 | 1,145 | $226,835 | $64,802 | 28.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 194 | 224 | $121,776 | $35,228 | 28.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 37 | 44 | $12,224 | $3,621 | 29.6% |
About Dr. Rahat Vohra, M.D
Dr. Rahat Vohra, M.D is a Internal Medicine healthcare provider based in Galveston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/09/2012. The National Provider Identifier (NPI) number assigned to this provider is 1154680320.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Rahat Vohra, M.D has received a total of $7,301 in payments from pharmaceutical and medical device companies, with $559.71 received in 2024. These payments were reported across 140 transactions from 19 companies. The most common payment nature is "Food and Beverage" ($7,263).
As a Medicare-enrolled provider, Vohra has provided services to 2,924 Medicare beneficiaries, totaling 8,963 services with total Medicare billing of $806,100. Data is available for 4 years (2020–2023), covering 17 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Galveston, TX
- Active Since 05/09/2012
- Last Updated 03/19/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1154680320
Products in Payments
- ZEMDRI (PLAZOMICIN) (Drug) $1,503
- NUZYRA (Drug) $541.19
- Arikayce (Drug) $529.58
- TEFLARO (Drug) $378.50
- Vabomere (Drug) $362.54
- Biktarvy (Drug) $346.69
- DOVATO (Drug) $321.74
- Baxdela (Drug) $276.02
- AVYCAZ (Drug) $253.29
- CABENUVA (Biological) $235.88
- VIBATIV (Drug) $204.12
- JULUCA (Drug) $160.50
- REBYOTA (Biological) $157.81
- Epclusa (Drug) $151.32
- Kimyrsa (Drug) $141.20
- ZERBAXA (Drug) $133.65
- RECARBRIO (Drug) $116.93
- TRIUMEQ (Drug) $115.20
- Vibativ (Drug) $114.40
- SILVERCEL (Device) $111.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Galveston
Tina Kochar, Md, MD
Internal Medicine — Payments: $236,481
Internal Medicine $236,481
Dr. Umamahesh Rangasetty, Mbbs, MBBS
Internal Medicine — Payments: $106,903
Internal Medicine $106,903
Mahran Shoukier, Md, MD
Internal Medicine — Payments: $70,439
Internal Medicine $70,439
Dr. Dustin Staloch, M.d, M.D
Internal Medicine — Payments: $30,925
Internal Medicine $30,925
Christopher Perez, M.d, M.D
Internal Medicine — Payments: $20,081
Internal Medicine $20,081
Tejo Musunuru, M.d, M.D
Internal Medicine — Payments: $17,724
Internal Medicine $17,724